Prothena is a clinical stage biotechnology company based in Ireland with its research and development located South San Francisco, CA, that was founded in 2012 as a spin-off from Elan. Prothena focuses on the discovery and development of new antibodies for the treatment of a broad range of diseases that result from protein mis-folding or abnormal cell adhesion. The company focuses on the discovery and development of therapeutic monoclonal antibodies that target disease-causing proteins. These therapies have broad application including AL and AA forms of amyloidosis (NEOD001), Parkinson’s disease and related synucleinopathies (PRX002), along with cell adhesion targets involved in inflammatory disease and metastatic cancers (PRX003). The company’s strategy is first to identify antibody candidates for clinical development by applying its extensive expertise in generating novel therapeutic antibodies and then to collaborate with experts in specific animal models of disease in advancing these therapies in preclinical and clinical studies.